TBRG

TruBridge (formerly Computer Programs and Systems) is a genuine turnaround: after two ugly years of net losses (-$48.1M in FY2023, -$20.9M in FY2024, likely impairment/restructuring-driven), FY2025 swung back to a $4.35M profit, operating income more than tripled to $20.8M (+227%), and operating cash flow grew to $37.0M (+18.7%). The MD&A explains the story — the business has pivoted from legacy EHR toward outsourced revenue-cycle management, now 64% of revenue, and the operating-margin recovery to 6.0% suggests that pivot plus cost discipline is starting to earn its keep. Crucially, the headline P/E of 90.5x is misleading: it's built on a still-depressed $0.29 EPS. On cash flow the stock is far more reasonable — ~$35.7M free cash flow (OCF $37.0M less $1.32M capex) against a $391M market cap is roughly 11x P/FCF, and the P/S of 1.1x is undemanding for a sticky, recurring-revenue services business with mid-to-high-90s retention.

The problem is that this is a low-growth business trading like it needs to grow. Revenue rose just 1.4% to $347M and has been essentially flat since FY2022 (~$327M→$347M). The Risk Factors are candid about why: the target market of community hospitals under ~400 beds (98% of Patient Care customers are under 100 beds) is an 'ever narrowing market,' and industry consolidation could shrink the client base and pressure prices. That structural ceiling means the thesis rests entirely on margin expansion and cross-selling Financial Health into the Patient Care base, not on top-line acceleration.